SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : Value Investing -- Ignore unavailable to you. Want to Upgrade?

To: Steve168 who wrote (20757)2/28/2005 12:37:25 PM
From: muwis123  Read Replies (1) | Respond to of 78742
 
I think BIIB is a better bet at this point. They may actually benefit from Elan's withdrawal of Tysabri. Biogen has another MS drug on the market called Avonex.



To: Steve168 who wrote (20757)2/28/2005 12:56:19 PM
From: Larry S.  Respond to of 78742
 
Oh, i thought ELN split 3:1 - finance.yahoo.com



To: Steve168 who wrote (20757)4/3/2005 12:22:16 AM
From: blankmind  Read Replies (1) | Respond to of 78742
 
Steve,

- any comment on your TFS rec - which is down quite a bit from you mentioned it - so @ $1.05 - is it a buy now?


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News